First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients-Reference-Cited by-同舟云学术

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients

Published:2013-11 Issue:11 Volume:24 Page:2773-2780
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Miles D.W.,Diéras V.,Cortés J.,Duenne A.-A.,Yi J.,O'Shaughnessy J.

Funder

F. Hoffmann-La Roche Ltd

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/11/2773/16700635/mdt276.pdf

Reference27 articles.

1. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer;Miles;Br J Cancer,2013

2. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial;Van Cutsem;J Clin Oncol,2012

3. E Van Cutsem G Jayson C Dive. Analysis of blood plasma factors in the AVITA phase III randomized study of bevacizumab (bev) with gemcitabine-erlotinib (GE) in patients (pts) with metastatic pancreatic cancer (mPC). European Multidisciplinary Cancer Congress23–27 September 2011Stockholm, Sweden(abstract 803)

4. Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer (MBC);O'Shaughnessy;Cancer Res,2009

5. Roche data on file 2007A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab (rhuMAb VEGF) as first-line therapy for locally recurrent or metastatic breast cancerClinical Study Report E2100

Cited by 193 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023;Bulletin du Cancer;2023-11

2. Promise and Challenges of T Cell Immunotherapy for Osteosarcoma;International Journal of Molecular Sciences;2023-08-07

3. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer;Molecular Cancer;2023-07-06

4. Target trial emulation to assess real-world efficacy in the Epidemiological Strategy and Medical Economics metastatic breast cancer cohort;JNCI: Journal of the National Cancer Institute;2023-05-23

5. Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial;BMC Cancer;2023-05-19